STOCKHOLM, SWEDEN / ACCESSWIRE / January 25, 2024 / PMD Device Solutions (STO:PROMO)(FRA:8T0) In Q1 2024, a market-leading ventilation company commences three separate clinical studies aimed at improving ventilation therapy of both hospitalised and homecare patients while using PMD Device Solutions AB’s ("PMD") novel device, RespiraSense, to optimise care outcomes by the continuous measurement of respiratory rate.
In Q1 2024, a market-leading ventilation company began three concurrently run clinical studies focusing on optimising ventilation therapy across countries spanning North America and Australasia while purchasing RespiraSense as the tool to monitor respiratory rate continuously. The number of patients to be recruited is not likely to exceed 300.
Respiratory rate is a leading indicator of respiratory failure. PMD has demonstrated that it can predict failure in patients 12 hours earlier than the standard of care, i.e. interim monitoring using pulse oximetry. Using RespiraSense in tandem with the intervention of ventilation support can transform the management of respiratory compromised patients and significantly improve outcomes. Patient recruitment for each of the studies will span the next 12-18 months, after which the results will be published by the ventilation company.
"RespiraSense is already used by existing hospital and homecare clinical teams to deploy ventilation support and optimise the therapy to the patient’s specific needs. Although PMD has a direct-to-market sales strategy, working with peers to improve patient outcomes is an arm of the Company’s growth and thought leadership strategy. Clinical studies are vital to any medical device Company’s marketing strategy. Their use of RespiraSense is a testament to the product’s clinical utility for supporting timely clinical decision-making." says PMD’s Founder and CEO Myles Murray.
PMD is not a sponsor of these studies and will not be reporting on the studies’ progress.
For additional information, please contact
Myles Murray, CEO
Phone: +353 86 887 4994
E-mail: myles@pmd-solutions.com & for general enquiries investor.relations@pmd-solutions.com
The Company’s Certified Adviser is Redeye.
Information about PMDS
PMD Device Solutions AB develops and sells medical products for respiratory monitoring in both the hospital and homecare setting. Its primary product is RespiraSense, a solution used for monitoring respiratory rate to support the detection of patient deterioration early and to avoid preventable respiratory failure and adverse patient outcomes. RespiraSense is, to the Company’s knowledge, the world’s only continuous, motion-tolerant respiratory rate monitor delivering class-leading reliability in measuring respiratory rate. RespiraSense is a novel technology that is commercialised in Europe, the UK, and FDA cleared in the US. The company’s shares are listed on Nasdaq First North Growth Market (STO: PMDS).
Attachments
RespiraSense selected by an industry-leading ventilation company for clinical studies.
SOURCE: PMD Device Solutions
View the original press release on accesswire.com